Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

NEW YORK, March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present recent clinical results today, Tuesday, March 15^th, at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (AD/PD 2022). The titled abstract, "Neurotrophic Restoration for Neurodegenerative Disease" summarizes therapeutic improvement by Bryostatin for advanced AD patients in placebo-controlled trials and its potential benefits for other neurodegenerative disorders such as Parkinson's Disease.

Read more at prnewswire.com